XASX
ADO
Market cap32mUSD
Oct 28, Last price
0.02AUD
1D
-5.26%
1Q
5.88%
Jan 2017
-54.05%
IPO
-99.39%
Name
Anteotech Ltd
Chart & Performance
P/E
—
P/S
106.63
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.21%
Rev. gr., 5y
10.75%
Revenues
460k
+25.89%
Net income
-9m
L-29.82%
CFO
-7m
L-19.33%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to-use kits to streamline and enhance the conjugation process; AnteoX, an additive that reinforces battery binders helping maximize performance of silicon containing anodes; EuGeni, a COVID-19 antigen rapid test; and AnteoRelease and AnteoCoat. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||